| 0.8735 0.442 (102.57%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.22  |
1-year : | 1.43 |
| Resists | First : | 1.04 |
Second : | 1.22 |
| Pivot price | 0.43 |
|||
| Supports | First : | 0.61 |
Second : | 0.34 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.43 |
| MA(100) : | 0.53 |
MA(250) : | 0.84  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55.3 |
D(3) : | 43.8 |
| RSI | RSI(14): 86.1 |
|||
| 52-week | High : | 2.38 | Low : | 0.27 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ HOWL ] has closed above the upper band by 42.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 121.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.05 - 1.05 | 1.05 - 1.06 |
| Low: | 0.85 - 0.86 | 0.86 - 0.86 |
| Close: | 0.87 - 0.87 | 0.87 - 0.88 |
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Fri, 21 Aug 2026
Why Is Werewolf Therapeutics Stock Gaining Friday? - Werewolf Therapeutics (NASDAQ:HOWL) - Benzinga
Fri, 21 Aug 2026
Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing - Yahoo Finance
Fri, 21 Aug 2026
HOWL Stock Whipsaws As One-Off Profit Meets Uncertain Future - StocksToTrade
Fri, 21 Aug 2026
Werewolf (NASDAQ: HOWL) Ambros deal leaves holders with single-digit stake - Stock Titan
Fri, 21 Aug 2026
Werewolf Therapeutics to Merge With Ambros in Stock Deal; Raises $150 Million PIPE, Holders Locked Up - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 26.7 (%) |
| Shares Short | 934 (K) |
| Shares Short P.Month | 965 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | -164.9 % |
| Operating Margin | 40.6 % |
| Return on Assets (ttm) | -27.4 % |
| Return on Equity (ttm) | -119.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.11 |
| Sales Per Share | 0.43 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.2 |
| PEG Ratio | 0 |
| Price to Book value | 1.71 |
| Price to Sales | 2.02 |
| Price to Cash Flow | -1.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|